The international team, including researchers from Oslo University Hospital (Norway), Acibadem University (Turkey), and the University Health Network in Toronto (Canada), aims to enhance diagnostic procedures through a combination of artificial intelligence (AI) and new laboratory technology. These methods will allow for the rapid and precise classification of tumor cells, making it easier to determine which therapies will be most effective and which the tumor may be resistant to.
“The software is already freely available worldwide for scientific purposes, but the collection of data to be fed into the software is still lengthy. With DC2M-TAEC, we will develop a faster and more accessible method,” says Professor Sahm, Deputy Medical Director of the Department of Neuropathology at the Institute of Pathology at the Heidelberg University Hospital.